
Asapiprant (BGE-175) is a мощный and specific антагонист of human PGD2/PTGDR signaling with Ki of 0.44 nM. BGE-175 is currently in a Phase 2 clinical trial to test whether it can prevent disease progression and mortality in older patients hospitalized wit
Asapiprant (BGE-175) is a potent and specific antagonist of human PGD2/PTGDR signaling with Ki of 0.44 nM. BGE-175 is currently in a Phase 2 clinical trial to test whether it can prevent disease progression and mortality in older patients hospitalized wit
Вращайте мышью · Колесо — масштаб
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.